You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Seattle, Washington 98109

  • Melanoma (Skin)


RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Study summary:

OBJECTIVES: Primary - Determine the safety and toxicity of cellular adoptive immunotherapy comprising autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens in patients with metastatic melanoma. - Determine the duration of in vivo persistence of this therapy in these patients. Secondary - Evaluate the antitumor effects of this therapy in these patients. OUTLINE: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells and then CD8+ cytotoxic T-lymphocyte (CTL) clones are generated ex vivo. Patients receive cellular adoptive immunotherapy comprising autologous CD8+ CTL clones targeting cancer testis antigens IV over 30 minutes on day 1. Patients also receive interleukin-2 subcutaneously every 12 hours on days 1-14 of courses 2-4. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a clinical response after completion of the fourth course are eligible to receive additional T-cell infusions. Patients are followed for 9 months. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 3 years.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic melanoma - Stage IV disease - HLA-A1, -A2, and -A3 positive - MAGE-1 or -3 positive by histology - Bidimensionally measurable disease by palpation on clinical examination, x-ray, or CT scan - No CNS metastases PATIENT CHARACTERISTICS: Age - 18 to 75 Performance status - Karnofsky 80-100% Life expectancy - More than 6 months Hematopoietic - Not specified Hepatic - Bilirubin ≤ 1.6 mg/dL - SGOT ≤ 3 times upper limit of normal - PT ≤ 1.5 times control Renal - Creatinine ≤ 2.0 mg/dL - Calcium ≤ 12 mg/dL Cardiovascular - No congestive heart failure - No clinically significant hypotension - No symptoms of coronary artery disease - No cardiac arrhythmias on electrocardiogram requiring drug therapy - Patients with prior cardiovascular disease or the presence of any of the above abnormalities undergo a cardiac evaluation, which may include a stress test and/or echocardiogram Pulmonary - No clinically significant pulmonary dysfunction by medical history or physical examination - FEV_1 ≥ 60% of normal - DLCO ≥ 55% (corrected for hemoglobin) Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No retinitis or choroiditis - No active infections or oral temperature greater than 38.2 degrees Celsius within the past 72 hours - No systemic infection requiring chronic maintenance or suppressive therapy PRIOR CONCURRENT THERAPY: Biologic therapy - No other concurrent immunotherapy (e.g., other interleukins, interferons, melanoma vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy) Chemotherapy - At least 3 weeks since prior standard or experimental chemotherapy - 1-2 courses of prior cytoreductive chemotherapy for bulky disease allowed Endocrine therapy - No concurrent systemic steroids (except for toxicity management) Radiotherapy - At least 3 weeks since prior radiotherapy Surgery - Not specified Other - At least 3 weeks since prior immunosuppressive therapy - No concurrent pentoxifylline - No other concurrent investigational agents



Primary Contact:

Study Chair
Cassian Yee, MD
Fred Hutchinson Cancer Research Center

Backup Contact:


Location Contact:

Seattle, Washington 98109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.